EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma

Feng Zhang, Wenfeng Liu, Fansheng Meng, Qiuyu Jiang, Wenqing Tang, Zhiyong Liu, Xiahui Lin, Ruyi Xue, Si Zhang, Ling Dong iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Feng Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Outstanding Youth Fund of Natural Science Foundation of Anhui Province, the Natural Science Foundation of Shanghai, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is an exceptionally immunosuppressive malignancy characterized by limited treatment options and a dismal prognosis. Macrophages constitute the primary and heterogeneous immune cell population within the HCC microenvironment. Our objective is to identify distinct subsets of macrophages implicated in the progression of HCC and their resistance to immunotherapy.

Methods

Intratumoral macrophage-specific marker genes were identified via single-cell RNA sequencing analyses. The clinical relevance of phospholipase A2 Group VII (PLA2G7), a pivotal enzyme in phospholipid metabolism, was assessed in patients with HCC through immunohistochemistry and immunofluorescence. Flow cytometry and an in vitro co-culture system were used to elucidate the specific role of PLA2G7 in macrophages. Orthotopic and subcutaneous HCC mouse models were employed to evaluate the potential of the PLA2G7 inhibitor in complementing immune checkpoint blockade (ICB) therapy.

Results

Single-cell RNA sequencing analyses disclosed predominant PLA2G7 expression in intratumoral macrophages within the HCC microenvironment. The macrophage-specific PLA2G7 was significantly correlated with poorer prognosis and immunotherapy resistance in patients with HCC. PLA2G7 high macrophages represent a highly immunosuppressive subset and impede CD8 T-cell activation. Pharmacological inhibition of PLA2G7 by darapladib improved the therapeutic efficacy of anti-programmed cell death protein 1 antibodies in the HCC mouse models.

Conclusions

Macrophage-specific PLA2G7 serves as a novel biomarker capable of prognosticating immunotherapy responsiveness and inhibiting PLA2G7 has the potential to enhance the efficacy of ICB therapy for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMiceAnimalsHumansMacrophagesImmunotherapyPrognosisTumor Microenvironment1-Alkyl-2-acetylglycerophosphocholine Esterase

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsMacrophagesTumor Microenvironment

Substanzen

PLA2G7 protein, human1-Alkyl-2-acetylglycerophosphocholine Esterase

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Shanghai Institute of Liver Disease, Shanghai, China.
  • Shanghai Medical College of Fudan University, Shanghai, China.
  • Shanghai Medical College of Fudan University, Shanghai, China dong.ling@zs-hospital.sh.cn zhangsi@fudan.edu.cn.
  • Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China dong.ling@zs-hospital.sh.cn zhangsi@fudan.edu.cn.

ORCID-Profile: Ling Dong

Förderung

  • the Outstanding Youth Fund of Natural Science Foundation of Anhui Province
  • the Natural Science Foundation of Shanghai
  • the National Natural Science Foundation of China

Zitieren

APA

Zhang, F., Liu, W., Meng, F., Jiang, Q., Tang, W., Liu, Z., Lin, X., Xue, R., Zhang, S., & Dong, L. (2024). Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008094

Vancouver

Zhang F, Liu W, Meng F, Jiang Q, Tang W, Liu Z, et al. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008094

BibTeX
@article{Zhang2024,
  author = {Zhang, Feng and Liu, Wenfeng and Meng, Fansheng and Jiang, Qiuyu and Tang, Wenqing and Liu, Zhiyong and Lin, Xiahui and Xue, Ruyi and Zhang, Si and Dong, Ling},
  title = {Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008094}
}
Kostenlos starten →